At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 807 enrolled
Drug / intervention
DVS SR +1 moredrug
Likely dose
DVS SR 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Paroxetine-referenced, Parallel-group Study to Evaluate the Safety, Efficacy, and Tolerability of 3 Fixed Doses (50mg, 100mg, AND 200mg) of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients With Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Mar 9, 2007·Updated Nov 4, 2013
In Brief
A Phase 3 clinical trial evaluating DVS SR and Paroxetine for Depressive Disorder, Major. Completed, enrolled 807 participants across 43 sites in 4 countries.
Detailed Summary
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesChina, India, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartJul 2007
Primary CompletionFeb 2009
TodayJul 2026
First PostedMar 9, 2007
Enrollment StartJul 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.3 years ago
Interventions
DVS SRdrug
Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
Paroxetinedrug
20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper